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ABSTRACT Although obesity is prevalent among children in the United States,
pharmacokinetic (PK) data for obese children are limited. Clindamycin is a commonly
used antibiotic that may require dose adjustment in obese children due to its lipo-
philic properties. We performed a clindamycin population PK analysis using data
from three separate trials. A total of 420 samples from 220 children, 76 of whom
had a body mass index greater than or equal to the 95th percentile for age, were
included in the analysis. Compared to other metrics, total body weight (TBW) was
the most robust measure of body size. The final model included TBW and a sigmoi-
dal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL
(liters/hour)  13.8  (TBW/70)0.75  [PMA2.83/(39.52.83PMA2.83)]; volume of distri-
bution (V) was associated with TBW, albumin (ALB), and alpha-1 acid glycoprotein
(AAG): V (liters)  63.6  (TBW/70)  (ALB/3.3)0.83  (AAG/2.4)0.25. After account-
ing for differences in TBW, obesity status did not explain additional interindividual
variability in model parameters. Our findings support TBW-based dosing for obese
and nonobese children.
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Childhood obesity has reached epidemic proportions in the United States. Over 17%of U.S. children meet the Centers for Disease Control and Prevention definition of
obesity, which is a body mass index (BMI) greater than or equal to the 95th percentile
for age (1). Obesity is associated with increased health care use and multiple adverse
health outcomes, including increased prevalence and severity of infections (2).
The relationship between obesity and infection remains to be fully elucidated.
However, one potential explanation for poor outcomes after infection may be subop-
timal antimicrobial dosing. Obesity results in important physiologic changes that may
have an impact on drug absorption, distribution, metabolism, and elimination. Specif-
ically, volume of distribution (V) may be affected by distribution of drug into excess
adipose tissue, while clearance (CL) may be affected by changes in renal function and
drug metabolism.
Despite the prevalence of childhood obesity, pharmacokinetic (PK) data for obese
children are limited. A recently published systematic review of PK studies that included
obese children identified only 20 studies of 21 medications published between 1970
and 2012 (3). Of these 20 studies, only four focused on antimicrobials. This review
identified clinically important PK changes in obese children compared to nonobese
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children for over half of the studied drugs. However, a drug’s physicochemical prop-
erties (lipophilicity and Biopharmaceutical Drug Disposition Classification System class)
did not predict the PK changes, highlighting the need for prospective PK studies with
obese children. Because antibiotics are the most common medication class prescribed
to children, additional studies of antimicrobials in obese pediatric patients are urgently
needed.
Clindamycin is particularly well suited for study in this population. It is a lipophilic
molecule that may require dose adjustment in obese patients. From a clinical perspec-
tive, clindamycin is widely used in the pediatric inpatient setting to treat invasive
infections for which optimal dosing is critical (4). From 1999 to 2008, 3% of all admissions
to freestanding children’s hospitals in the United States were due to Staphylococcus aureus
infections. Overall, two-thirds of these children received clindamycin, and 90% of
children with skin and soft tissue infections (SSTIs), to which obese children are
predisposed, received clindamycin.
It is essential to identify the optimal dosing for antibiotics, both to maximize cure
and to reduce the development of antimicrobial resistance. Because of its extensive use
in the pediatric population, specifically for conditions commonly associated with
obesity, clindamycin is a priority drug for dose optimization in obese children. There-
fore, the objectives of this study were to describe the PK of clindamycin in obese
children compared to nonobese children using data from three prospective PK studies.
RESULTS
Participant characteristics. Four hundred twenty samples from 220 children were
included in the analysis. These included 89 samples from 21 children who received
intravenous clindamycin in the Safety and Pharmacokinetics of Multiple-Dose Intrave-
nous and Oral Clindamycin in Pediatric Subjects with BMI  85th Percentile trial
(CLIN01; NICHD-2012-CLN01, ClinicalTrials.gov NCT01744730; IND 115,396), 267 sam-
ples from 178 children in the Pharmacokinetics of Understudied Drugs Administered to
Children per Standard of Care study (PTN POPS; NICHD-2011-POP01, ClinicalTrials.gov
NCT01431326; IND 113,645), and 64 samples from 21 children in the Pharmacoki-
netics of Antistaphylococcal Antibiotics in Infants study (Staph Trio; NICHD-2012-
STA01, ClinicalTrials.gov NCT01728363; IND 115,396). Demographic and clinical
characteristics are summarized in Table 1. In total, 76 children had a BMI greater
than or equal to the 95th percentile for age: 13 from CLIN01 and 63 from PTN POPS.
Thirty participants had a BMI greater than the 99th percentile for age. The remaining
144 children (8 from CLIN01, 115 from PTN POPS, and 21 from Staph Trio) were not
obese but were included in the analysis to create a robust model that accounted for
variations in PK across age and BMI spectra.
TABLE 1 Demographic and clinical characteristics for participants in the CLIN01, PTN
POPS, and Staph Trio trialsa
Covariate
Value in study
CLIN01 (n  21) PTN POPS (n  178) Staph Trio (n  21)
Ageb 13.0 (6.5–17.4) 5 (0.01–20.5) 23 (5–65)
Wt (kg) 69.5 (27.9–224) 23.0 (0.5–139.8) 1.0 (0.5–3.0)
BMI (kg/m2) 27.1 (18.6–74) 24.8 (13.7–46.7) NA
SCR (mg/dl) 0.6 (0.3–1.5) 0.4 (0.1–3.4) 0.7 (0.2–1.5)
AST (U/liter) 25 (8–151) 35.5 (8–389) 25 (15–116)
ALT (U/liter) 25 (10–114) 31.5 (5–266) 11 (6–55)
TBIL (mg/dl) 0.5 (0.2–3.8) 1.1 (0–11) 4.7 (0.5–8.2)
Albumin (g/dl) 3.7 (2.1–4.6) 3.3 (1.9–4.5) 2.3 (1.3–2.8)
AAG (mg/ml) 2.0 (0.5–3.8) 2.5 (0.5–6.3) 0.8 (0.4–1.8)
aData are medians (ranges). Descriptive statistics are calculated based on values at the time of first recorded
dose. PTN POPS, Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care;
CLIN01, Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric
Subjects with BMI  85th Percentile; Staph Trio, Pharmacokinetics of Antistaphylococcal Antibiotics in
Infants; BMI, body mass index; SCR, serum creatinine; AST, aspartate aminotransferase; ALT, alanine
transaminase; TBIL, total bilirubin; AAG, alpha-1 acid glycoprotein; NA, not available.
bAge is reported in years for CLIN01 and PTN POPS and days for Staph Trio.
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Population PK (popPK) model development and evaluation. Plasma clindamycin
concentrations over time are presented in Fig. 1. Consistent with previous studies, a
one-compartment PK model described the clindamycin concentration-versus-time data
well (5, 6). Body weight was assumed to be a significant predictor of CL and V and was
incorporated into the base model before evaluation of other covariates. Because the
optimal dosing weight for clindamycin in obese children was uncertain, total body
weight (TBW) was compared with normal fat mass (NFM), free fat mass (FFM), and lean
body weight (LBW). Height was missing for all 21 neonates from Staph Trio and 6/178
(3%) children from PTN POPS, so NFM, FFM, and LBW were not calculated. TBW resulted
in the lowest objective function value (OFV) (7,157.9 for TBW, 7,173.0 for FFM, 7,173.0
for NFM, and 7,164.8 for LBW); therefore, all additional covariate models were evaluated
after accounting for TBW (see Table S5 in the supplemental material).
After accounting for TBW, use of a sigmoidal maturation function for CL with postmen-
strual age (PMA) resulted in the largest drop in the OFV. On univariable analysis, total
bilirubin, serum creatinine (SCR), albumin (ALB), and alpha-1 acid glycoprotein (AAG) on
CL and AAG, ALB, and obesity (BMI  95%) on V resulted in a significant drop in OFV
and were included in multivariable analysis. On multivariable analysis, forward addition
of SCR on CL and ALB and AAG on V resulted in a significant drop in the OFV, but only
FIG 1 Clindamycin concentration versus time for merged data set of the Safety and Pharmacokinetics of
Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects with BMI  85th Percentile
(CLN01), Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care
(POP01), and Pharmacokinetics of Antistaphylococcal Antibiotics in Infants (Staph Trio [STA01]) trials (A)
and the CLN01 trial only (B).
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ALB and AAG on V were retained after backward elimination (Table 2). Although
backward elimination of SCR reached statistical significance, it was not included in the
model, as this significance was due to one individual participant with SCR of 3.4 mg/dl.
The following relationships characterized the typical values for CL and V in the final
model:
CL liters/hour 13.8 TBW/700.75 PMA2.83 ⁄ 39.52.83 PMA2.83
V liters 63.6 (TBW/70) (ALB/3.3)0.83 (AAG/2.4)0.25
Maturation reached 50% adult CL values at 40 weeks PMA, with near complete
maturation by 2 years of age. Diagnostic plots for the final model are shown in Fig. S1
in the supplemental material. Visual predictive checks including all data and stratified
by study are shown in Fig. S2. Shrinkage estimates were 30% for all random effect
parameters. In sensitivity analysis, after exclusion of data from children 2 years of age
and the maturational function between CL and PMA, there were clinically insignificant
differences (15%) in fixed effects parameters with the final model using the reduced
data set (Table S6).
Empirical Bayesian estimates for children 2 years of age were obtained from the
final model and stratified by obesity status and age (Table 3). For the 6- to 12-year
and 12-year age categories, statistically significant differences were observed in the
absolute (i.e., non-weight normalized) V estimates (P  0.001). Half-life of elimination
was also significantly different, but only for the6- to 12-year age group (P 0.01). No
TABLE 2 Population pharmacokinetic parameter estimates for the final modela
Parameter
Final model Bootstrap (n  1,000)
Estimate RSE (%) 2.5th percentile Median 97.5th percentile
CL70kg (liters/h) 13.8 6.2 12.3 13.8 15.7
V70kg (liters) 63.6 5.0 59.0 64.1 71.4
TM50 (wks) 39.5 12.1 32.5 39.4 53.4
HILL 2.8 33.7 1.5 3.0 5.1
Albumin on V exponent 0.83 27.9 1.29 0.87 0.43
Alpha-1 acid glycoprotein
on V exponent
0.25 44.0 0.41 0.25 0.03
IIV (CL) (%) 58.5 11.5 52.1 58.4 64.8
IIV (V) (%) 11.6 145.5 5.9 15.7 27.9
 CL-V 0.8 64.5 0 0.7 0.8
Prop., PTN POPS (%) 33.6 16.5 26.7 32.7 38.0
Prop., Staph Trio (%) 32.1 28.8 19.3 31.1 40.1
Prop., CLIN01 (%) 20.3 30.4 13.0 18.7 25.0
aRSE, relative standard error; CL70kg, population clearance estimate scaled to a 70-kg adult; V70kg, population
volume of distribution estimate scaled to a 70-kg adult; TM50, maturation half-life calculated as a function
of PMA; HILL, Hill coefficient in sigmoidal maturation function; IIV (CL), interindividual variability in drug
clearance; IIV (V), interindividual variability in volume; PTN POPS, Pharmacokinetics of Understudied Drugs
Administered to Children per Standard of Care; Staph Trio, Pharmacokinetics of Antistaphylococcal
Antibiotics in Infants; CLIN01, Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral
Clindamycin in Pediatric Subjects with BMI  85th Percentile; Prop., proportional residual error.
TABLE 3 Comparison of empirical Bayesian estimates for the final model using total body weight to correct for body size
Parameter
Median (range) for age categorya
>2–6 yrsb >6–12 yrs >12 yrsc
Nonobese (n  8) Obese (n  12) Nonobese (n  15) Obese (n  20) Nonobese (n  26) Obese (n  44)
CL (liters/h) 4.17 (0.90–9.10) 5.69 (1.84–8.27) 12.50 (3.55–34.40) 10.70 (4.71–26.70) 14.25 (5.56–37.40) 19.15 (3.92–33.70)
CL (liters/h/kg) 0.23 (0.082–0.78) 0.28 (0.11–0.40) 0.33 (0.13–0.78) 0.22 (0.092–0.64) 0.23 (0.064–0.53) 0.18 (0.041–0.65)
CL (liters/h/70 kg) 10.64 (3.59–35.03) 14.83 (5.49–20.32) 20.67 (7.08–48.48) 14.69 (5.94–39.16) 15.82 (4.72–34.68) 13.97 (3.12–37.89)
V (liters) 15.25 (7.58–19.70) 17.60 (8.39–25.20) 29.0 (17.50–57.40) 46.90 (32.90–85.80)** 60.10 (22.50–94.60) 85.75 (28.50–160.0)**
V (liters/kg) 0.81 (0.69–1.26) 0.86 (0.66–1.03) 0.90 (0.67–1.06) 1.03 (0.66–1.29) 0.89 (0.70–1.34) 0.89 (0.62–1.58)
Half-life (h) 2.41 (1.12–5.85) 2.15 (1.53–4.36) 2.15 (0.95–5.77) 3.03 (1.19–6.26)** 2.84 (1.17–7.60) 3.55 (0.90–11.30)
aStatistically significant differences (**) were observed using a rank sum test.
bThree participants with missing height (and BMI) were not included in this parameter summary.
cTen participants (6 nonobese and 4 obese) who were 18 years of age were included in the parameter summary.
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other statistically significant differences were observed between obese and nonobese
children. Parameter estimates from the sensitivity analysis were within 15% of those
from the full model (Table S7), with the same qualitative results; absolute (not weight-
normalized) V in children6 years and half-life of elimination in the6- to 12-year age
group were the only significant differences between obese and nonobese children.
Dosing simulations. The median simulated total drug steady-state areas under the
curve from 0 to 8 h (AUC0–8,SS) when stratified by age-based dosing were 44.2 g · h/ml
for ages 2 to 6 years (12 mg/kg every 8 h), 44.8 g · h/ml for ages 6 to 12 years (10
mg/kg every 8 h), and 48.6 g · h/ml for ages 12 years (10 mg/kg every 8 h). The
median exposures of these dosing regimens were within 25% of the median observed
in a 70-kg simulated adult receiving 600 mg intravenously every 8 h: 44.7 g · h/ml. A
box plot stratified by age and obesity status is shown in Fig. 2.
Simulated maximal drug concentrations at steady state (Cmax,SS) were also within
20% of that simulated for a 70-kg adult receiving 600 mg every 8 h (12.2 g/ml): 14.1
g/ml for ages 2 to 6 years (12 mg/kg every 8 h), 12.2 g/ml for ages 6 to 12 years
(10 mg/kg every 8 h), and 12.2 g/ml for ages 12 years (10 mg/kg every 8 h). A box
plot stratified by age and obesity status is shown in Fig. 3. After correcting for protein
binding and using the optimal dosing regimens described above, the simulated
unbound, steady-state clindamycin concentrations were above an MIC of 0.12 g/ml
for at least half the dosing interval in 80% of participants across age groups.
Safety. In obese children in the CLIN01 study, clindamycin was very well tolerated.
Three adverse events, including one serious event, were reported for 2 (9%) CLIN01
participants; none of the adverse events were considered related to the study drug. The
serious adverse event consisted of an apneic event that occurred and resolved after
consent but before administration of the study drug. One other participant experienced
2 adverse events: moderate worsening of rash and development of a moderate right
internal jugular vein thrombus.
DISCUSSION
This is the first study to assess the effect of obesity on clindamycin PK; our model
supports clindamycin dosing based on TBW for obese and nonobese children.
Multiple methods have been suggested for dosing antimicrobials in obese patients,
but there is no clear consensus. Adult studies suggest that the most appropriate metric
for dosing weight varies by specific drug and differs even among medications with
FIG 2 Box plot of simulated total drug steady-state area under the curve (AUC) from 0 to 8 h following age-based clindamycin dosing and stratified by obesity
status. Dosing was 12 mg/kg every 8 h for ages 2 to 6 years and 10 mg/kg every 8 h for ages 6 years, with a maximum dosage of 900 mg every 8 h. The
upper and lower whiskers extend to the highest and lowest points that are within 1.5 times the interquartile range.
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similar physicochemical profiles. There are very limited data for obese children, making
choice of a dosing metric difficult. We evaluated alternative measurements of body
composition, including FFM, NFM, and LBW, compared with the use of TBW. Each of
these measures increased the objective function relative to use of TBW. This suggests
that TBW is the most robust measure of accounting for variation in CL and V for
clindamycin.
After accounting for TBW, the additional effect of obesity status on clindamycin PK
was nonsignificant. The limited impact of obesity on clindamycin PK was verified in the
empirical Bayesian estimates derived from the final model. Although there were
statistically significant differences between absolute V in obese compared to nonobese
children, these differences did not persist after adjusting for TBW. This suggests that
clindamycin distributes into excess weight as would be expected given its lipophilic
profile. Additionally, simulations were performed using the final model to assess dosing
in obese and nonobese children using recommended age-based intravenous dosing.
Simulated doses were comparable to those for a 70-kg adult receiving standard
clindamycin dosing regardless of obesity status.
In the final model, V was also associated with ALB and AAG. This is not surprising,
as clindamycin is highly bound to serum proteins (7). Although clindamycin primarily
binds to AAG, it also binds to ALB (8). In the final model, ALB was a more significant
predictor of V. This may have occurred because AAG is present in serum in much
smaller concentrations than ALB. Although clindamycin has a higher affinity for
AAG, binding to AAG may reach saturation at lower drug concentrations, allowing
for changes in serum ALB to account for greater variability in V (8). The only other
covariate that was included in the final model was PMA, which was included in the
analysis to account for expected maturational changes in infants but did not impact CL
estimates in children 2 years of age.
There is a paucity of PK studies of antimicrobials in obese children. In the only other
published prospective PK study for this population, five obese children (BMI  95th
percentile) were administered single doses of cefazolin and tobramycin (9). The tobra-
mycin V adjusted for TBW was significantly lower in obese than in nonobese children;
there were no differences for tobramycin CL or either parameter for cefazolin. Similarly,
retrospective studies of gentamicin (10) and vancomycin (11, 12) concentrations col-
lected as part of clinical care found that obese children had significantly higher drug
FIG 3 Box plot of simulated maximal drug concentration at steady state (Cmax,SS) following age-based clindamycin dosing and stratified by obesity status.
Dosing was 12 mg/kg every 8 h for ages 2 to 6 years and 10 mg/kg every 8 h for ages 6 years, with a maximum dose of 900 mg every 8 h. The upper and
lower whiskers extend to the highest and lowest points that are within 1.5 times the interquartile range.
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concentrations than nonobese controls, suggesting that alternate measures of body
weight, such as LBW, may be needed for dosing of these drugs in obese children.
Vancomycin, cefazolin, and the aminoglycosides are hydrophilic molecules. In con-
trast, clindamycin is lipophilic. Therefore, it might be expected to have a higher
absolute V in obese patients. Few studies have reported clindamycin PK in the setting
of obesity. Appropriate dosing is particularly important in bone and joint infections, for
which adequate tissue concentrations are needed to achieve clinical cure. An adult
study used a population PK model to assess adequate dosing in 50 patients being
treated for osteomyelitis, 4 of whom were obese (BMI  30 kg/m2) (6). Assuming a
Staphylococcus aureus MIC of 0.125 mg/liter and clindamycin bone penetration of 30%,
the researchers concluded that the standard adult dosage of 600 mg intravenously
every 8 h achieved adequate serum concentrations in adults up to 75 kg but that 900
mg intravenously every 8 h should be used in adults weighing 75 kg. This 2.7-g/day
dosage coincides with the maximum labeled dose for clindamycin used in clinical
practice and was the maximum study dose in the current analysis.
Our data suggest that TBW-based clindamycin dosing should achieve sufficient
bone concentrations for the treatment of osteomyelitis in obese children. Regardless of
obesity status, simulated doses using TBW achieved clindamycin exposures comparable
to those in adults receiving 600 mg intravenously every 8 h, the dosage recommended
for osteomyelitis in national guidelines (13) and supported by popPK modeling in
adults (6). Further, clindamycin bone concentrations obtained from adults undergoing
total hip replacement demonstrate that doses as low as 300 mg, given either intra-
muscularly (14) or intramuscularly and intravenously (15), achieve concentrations well
above the staphylococcal MIC for clindamycin.
Because of small sample sizes, previous PK studies of obese children may have been
underpowered to detect differences in PK parameters in obese compared to nonobese
children. A strength of the present analysis is that it leveraged PK samples from three
separate trials to create a robust popPK model. This allowed us to create the largest
cohort of obese children included in a prospective PK analysis to date. However, this
approach does have some limitations. The inclusion of different study designs and
populations likely introduces additional variability into the model. For this reason,
separate proportional residual errors were used for each study. Laboratory data (par-
ticularly aspartate transaminase [AST], alanine transaminase [ALT], total bilirubin, and
ALB) were missing for many of the participants in PTN POPS. Missing values were
imputed using median values for the sample, which might have underestimated
the impact of these variables on clindamycin PK. Measurements of height and weight
were required study procedures for CLIN01, but height and weight were abstracted
from the medical record for PTN POPS. This may have resulted in incorrect BMI
assessments and misclassification of obesity status for some participants. Additionally,
while BMI is a commonly used metric to determine obesity, it is not a direct measure
of adiposity. Athletic children with increased muscle mass would have met our BMI-
based criteria for obesity without being truly obese. Use of skinfold assessments might
provide a useful alternative measure of adiposity for PK studies in obese children
moving forward. We did not model clindamycin dosing based on body surface area
(BSA). Although the current label provides dosing based on BSA as an alternative to
dosing by body weight, this is not commonly used in clinical practice. National
guidelines for MRSA bone/joint infections and skin and SSTIs (13), community-acquired
pneumonia (16), and sinusitis (17) all recommend weight-based clindamycin dosing for
children. In post hoc analyses, the OFVs obtained using BSA were higher than those
obtained using TBW, so we did not pursue this strategy. Finally, we cannot comment
on the optimal dosing for children weighing 90 kg whose TBW-based dose
exceeds the labeled maximum adult dosage of 2.7 g/day. The CLIN01 protocol
allowed dosing 2.7 g/day only if it was being used as part of standard-of-care
treatment. However, only one adolescent received a dosage of 900 mg every 8 h.
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Conclusion. Data from three separate trials were combined to create a popPK
model to assess the impact of obesity on clindamycin PK. Compared to FFM, NFM,
and LBW, TBW was the most appropriate metric for clindamycin dosing in obese
and nonobese children.
MATERIALS AND METHODS
Patient population. PK and safety data were obtained from patients receiving intravenous clinda-
mycin in the Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric
Subjects with BMI  85th Percentile trial (CLIN01; NICHD-2012-CLN01, ClinicalTrials.gov NCT01744730;
IND 115,396). CLIN01 was a prospective, multicenter (n  6), open-label, multiple-dose PK and safety
study of intravenous and oral clindamycin. Pediatric participants were enrolled in the trial if they met the
following inclusion criteria: age of 2 to 18 years at the time of first dose of study drug, suspected or
confirmed infection or receiving intravenous clindamycin per standard of care, negative pregnancy test,
BMI greater than or equal to the 85th percentile for age and sex based on Centers for Disease Control
and Prevention recommendations, signed informed consent, and assent where required. Exclusion
criteria included exposure to current potent CYP3A4 inducers and inhibitors. Patients who were post-
cardiac bypass (within 24 h) or receiving inotropes/vasopressors were also excluded. For participants not
receiving clindamycin per standard of care, additional exclusion criteria included history of hypersensi-
tivity or allergic reaction to clindamycin or lincomycin, history of Clostridium difficile colitis with previous
administration of clindamycin, aspartate transaminase (AST) of 120 U/liter, alanine transaminase (ALT)
of 210 U/liter, total bilirubin of 3 mg/dl, and receipt of a neuromuscular blocker as part of their
therapy. Data from two additional trials were included in the popPK model development: the Pharma-
cokinetics of Understudied Drugs Administered to Children per Standard of Care (PTN POPS; NICHD-
2011-POP01, ClinicalTrials.gov NCT01431326; IND 113,645) study and the Pharmacokinetics of Anti-
staphylococcal Antibiotics in Infants (Staph Trio; NICHD-2012-STA01, ClinicalTrials.gov NCT01728363; IND
115,396) study. Full details of these two studies have been previously published (5, 18). Briefly, PTN POPS
was a multicenter (n  27), prospective PK and safety study of understudied drugs (including clinda-
mycin) administered to children (obese and nonobese,21 years of age) per standard of care. Staph Trio
was a multicenter (n  8), prospective, multiple-dose PK and safety study of clindamycin, rifampin, and
ticarcillin-clavulanate in premature infants. PK samples from neonates and nonobese children in these
additional studies were included in the main analysis to develop a robust population PK model designed
to describe clindamycin disposition across all pediatric age groups and body types. However, a sensitivity
analysis was performed excluding all data from Staph Trio and data from children less than 2 years of age
in PTN POPS.
Drug dosing and sample collection. In the CLIN01 trial, intravenous clindamycin was prescribed at
a dosage of 30 to 40 mg/kg/day based on total body weight (TBW) every 6 or 8 h. Optimal PK sampling
times are presented in Table S1 in the supplemental material.
For the PTN POPS study, dosing information was collected for up to eight doses prior to the sampling
dose (last dose before first biological sample collection). Due to the opportunistic study design, the
timing of blood sample collection was dependent on standard-of-care laboratory assessments. However,
parents/guardians were also given the option to allow sample collection for research purposes only
(Table S2).
In the Staph Trio trial, all infants received clindamycin at 10 mg/kg every 6, 8, or 12 h unless
prescribed clindamycin per standard of care, in which case dosing was at the discretion of the treating
caregiver. The dosing interval and sampling schedule were stratified by gestational age (GA) and
postnatal age (PNA) (Tables S3 and S4). Up to eight PK samples were collected based on the predeter-
mined sampling window.
Analytical methods. For all studies, blood was collected (200 l) in an EDTA-K2 Microtainer and was
processed immediately prior to freezing at the study sites. PK samples were sent to the Pediatric Trials
Network central laboratory (OpAns, LLC, Durham, NC) for storage and analysis. Clindamycin concentra-
tions collected from the three trials were quantified using a validated liquid chromatography-tandem
spectrometry assay. The chromatography system and mass spectrometer used for sample analysis were
the Agilent 1200 series high-performance liquid chromatography system and an Agilent 6400 series
triple quadrupole system, respectively. The Pursuit XRS Ultra C18 column (50 by 2 mm; inside diameter
[i.d.], 2.8 m; Agilent) and a gradient mobile phase (water containing 0.5% [vol/vol] formic acid;
methanol containing 0.1% [vol/vol] formic acid) were used. The validation range for the assay was 50 to
50,000 ng/ml. Quality control samples included the following nominal concentrations: 50, 150, 4,000, and
40,000 ng/ml. The lower limit of quantification was 50 ng/ml. Accuracy and precision assessed using five
determinations at theoretical levels 50, 150, 4,000, and 40,000 ng/ml were within the Food and Drug
Administration bioanalytical assay validation criteria (e.g., 	15%).
Model development. Clindamycin plasma PK data collected following intravenous administration
were analyzed with a nonlinear mixed effects modeling approach using the software NONMEM (version
7.2; Icon Development Solutions, Ellicott City, MD). The first-order conditional estimation method with
interaction was used for all model runs. Run management was performed using Pirana (version 2.8.1)
(19). Visual predictive checks and bootstrap methods were performed with Perl-speaks-NONMEM (ver-
sion 3.6.2) (20). Data manipulation and visualization were performed using the software R (version 3.0.2;
R Foundation for Statistical Computing, Vienna, Austria) and RStudio (version 0.97.551; RStudio, Boston,
MA), with the packages lattice, Xpose, and ggplot2 used for the latter (21–23).
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Based on our previously published popPK model, a one-compartment model was used in the
analyses described herein (5). Between-subject variability was assessed for PK model parameters using
an exponential relationship (equation 1):
Pij 	Pop,j exp(
ij) (1)
where Pij is the estimate of parameter j in the ith individual, 	Pop,j is the population value for parameter
j, and 
ij is the deviation from the average population value for parameter j in the ith individual with
mean zero and variance 2. The correlation between random effect parameters was calculated according
to equation 2, and a proportional error model was used to estimate the intraindividual variability
(equation 3):
 
CL,V
CL2V2
(2)
Cobs,ij Cpred,ij (1 prop,ij) (3)
where CL,V is the off-diagonal element between CL and V, Cobs,ij is the jth observed clindamycin
concentration in the ith individual, Cpred,ij is the jth predicted concentration in the ith individual, and
prop,ij is a random variable with mean zero and variance prop,ij2. Because data were combined from the
three trials, separate proportional residual errors were used for each study.
The final popPK model included a relationship between TBW and postmenstrual age (PMA) with CL
and V as depicted in equations 4 and 5 (5):
CL CLstd TBWi70 kg 
0.75

PMAHILL
TM50
HILL PMAHILL
(4)
V Vstd TBWi70 kg 
1
(5)
where CLstd and Vstd represent population estimates of CL and V in a 70-kg adult, TBWi is total body
weight for the ith subject, HILL is a slope parameter for the sigmoidal maturation model, and TM50 is the
value of PMA (weeks) when 50% adult clearance is reached.
Alternative measures of body composition. To assess whether use of other measures of body
composition—normal fat mass (NFM), fat free mass (FFM), and lean body weight (LBW)—resulted in
superior model performance, we tested these first in place of TBW and in the absence of accounting
for PMA.
(i) FFM. FFM is a sex-specific estimate of body weight that excludes weight due to fat. FFM was
estimated using the following equation (24):
FFMWHSmax H
2 	 TBW
(WHS50 H
2 TBW)

 (6)
WHSmax and WHS50 are sex-specific values: WHSmax  42.92 kg/m2 and WHS50  30.93 kg/m2 for men;
WHSmax  37.99 kg/m2 and WHS50  35.98 kg/m2 for women. If height was missing, TBW was used in
place of FFM.
(ii) NFM. NFM accounts for the differential impact of fat mass and FFM on PK. NFM was estimated
using the following equation (25):
NFM FFM Ffat (TBW FFM) (7)
The parameter Ffat is not constant but is estimated from the observed data for a given drug and accounts
for different contributions of fat for each PK parameter (e.g., CL and V). If height was missing, NFM was
assumed to be 90% TBW.
(iii) LBW. LBW measures body weight that is not due to water. We applied an approach whereby
estimated extracellular fluid volume (eECV) is calculated from TBW and height (H) (26):
eECV 0.0215 TBW0.6469 H0.7236 (8)
LBW 3.8 eECV (9)
If height was missing, TBW was used.
Covariate analysis. Following assessment of the ideal measure of weight, additional covariates
were tested for model inclusion, beginning with PMA, which was in the originally published model.
Determination of which covariates to test for model inclusion was made by visual inspection of scatter
and box plots (continuous and categorical variables, respectively) of the individual deviations from the
population-typical value PK parameters (ETAs) against covariates. The following covariates were ex-
plored: PMA (years), ALT (units/liter), AST (units/liter), serum creatinine (SCR; milligrams/deciliter), biliru-
bin (total and direct, milligrams/deciliter), albumin (ALB; grams/deciliter), alpha-1 acid glycoprotein (AAG;
milligrams/milliliter), BMI, obese status (BMI  95th percentile for age), ethnicity, and sex. A forward
inclusion (P  0.05 and Δ in objective function value [ΔOFV] of 3.8) and backward elimination (P 
0.001 and ΔOFV  10.8) approach was used to evaluate statistical significance of all covariates.
Population PK model evaluation and validation. During assessment of covariates and measures of
weight, standard model diagnostic methods were used and included successful minimization, diagnostic
plots, plausibility and precision of parameter estimates, and objective function and shrinkage values.
Diagnostic plots generated included individual predictions and population predictions versus observa-
tions, conditional weighted residuals versus population predictions and time, and individual weighted
residuals versus individual predictions. Parameter precision for the final popPK model was evaluated
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using nonparametric bootstrapping (1,000 replicates) to generate the 95% confidence intervals for
parameter estimates. Visual predictive checks were performed whereby the base and final models were
used to generate 1,000 Monte Carlo simulation replicates per time point of clindamycin exposure, and
simulated results were compared with those observed in the study. The dosing and covariate values used
to generate the simulations in the visual predictive check were the same as those used in the study
population.
A sensitivity analysis was performed excluding all children younger than 2 years of age. Because such
children cannot by definition be obese, their inclusion may have biased our parameter estimates.
Population and individual estimates were first derived from the final model excluding children 2 years
old. Subsequently, the maturational function between PMA and CL was dropped from the model, as
neonates and infants were excluded from this limited data set.
Model-based simulations to assess pediatric dosing. The final model parameter estimates were
used to perform dosing simulations. Age-based dosing regimens of 12 mg/kg every 8 h for children 6
years old and 10 mg/kg every 8 h for children 6 years old were chosen because they were previously
shown to match adult (70 kg) clindamycin exposure of 600 mg every 8 h (5). The following parameters
were calculated for each virtual subject: steady-state area under the curve from 0 to 8 h (AUC0–8,SS),
maximal drug concentrations at steady state (Cmax,SS), and minimum concentration at steady state
(Cmin,SS). Model equations are shown in equations 10 to 12:
AUC08,ss
dose
CL
(10)
Cmax,SS
dose
(CL DUR)

1 exp(kel DUR)
1 exp(kel )
(11)
Cmin,SS Cmax,SS expkel (  DUR) (12)
where kel is the first-order elimination rate constant, calculated as CL/V; DUR is the infusion duration (0.5
h for all dosing simulations); and  is the dosing interval (8 h for all dosing simulations).
The covariate values for virtual patients were the same as those in the study population used for
model development. Using PK parameter estimates from the final population model, 200 concentration-
versus-time profiles were simulated for each virtual patient and then related to adult simulated exposure.
Patients who would receive 900 mg following weight-based dosing (75 kg for 12 mg/kg and 90 kg
for 10 mg/kg) received a maximum dose of 900 mg. Unbound, steady-state clindamycin concentrations
at half the dosing interval (fC50,SS) were calculated assuming a fraction unbound of 6% (7, 27). The
proportion of virtual participants with an fC50,SS greater than a MIC of 0.12 g/ml (MIC90 for Staphylo-
coccus aureus) following optimal dosing was calculated (28).
Safety. Participants in CLIN01 were monitored for safety. All participants who received at least one
dose of study drug were included in the safety analysis. Participants were followed for adverse events
during study drug administration through 3 days after discontinuation of study drug. Additionally,
laboratory assessments (hematology and biochemistry) were obtained within 72 h prior to the first study
dose and within 24 h of last study dose on all participants.
Statistical analysis. Using the value at the time of first recorded dose, the median and range were
calculated for demographic and clinical variables. We tested the equality of distribution of each PK
parameter of interest among the obese and nonobese population using the nonparametric Wilcoxon
rank sum test and stratified the analysis by participant age: 2 to 6 years, 6 to 12 years, and 12 years.
With the exception of the PK modeling, all statistical analyses were performed using the software R
(version 3.0.2; R Foundation for Statistical Computing, Vienna, Austria) or Stata (version 13.1; College
Station, TX).
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